Predict your next investment

Novolytics - Bacteriophage Assets

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Acquired Unit | Acquired

About Novolytics - Bacteriophage Assets

Novolytics, formed in 2002, engages in the research, development, and production of phage therapy products to combat antibiotic resistance.

Novolytics - Bacteriophage Assets Headquarter Location

Sumner House St. Thomas's Road

Lancashire, England, PR7 1HP,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.